Mednet Logo
SpecialtiesPediatric Hematology/Oncology
Pediatric Hematology/Oncology

Pediatric Hematology/Oncology

Clinical discussions on pediatric blood disorders, childhood cancers, and specialized treatment protocols.

Recent Discussions

Have you used oral vancomycin as prophylaxis for C difficile infection in patients admitted for allogeneic hematopoietic cell transplant?

1
2 Answers

Mednet Member
Mednet Member
Infectious Disease · National Institute of Allergy and Infectious Diseases (NIAID)

Yes, but only in patients with a history of C difficile in the previous year and starting at the time of initiation of broad-spectrum antibiotics (e.g., for fever and neutropenia). We use 125 mg daily.We are aware this practice may be controversial. To my knowledge, there is only one randomized tria...

Would you consider TPO mimetics for chemotherapy induced thrombocytopenia that persists despite dose reductions?

1
1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Weill Medical College of Cornell University

The reported evidence on using a TPO-RA in chemotherapy-induced thrombocytopenia (CIT) is complicated but this seems like a situation where it is worth trying a TPO-RA. Repeated dose reduction and/or delay is not good for treatment of a cancer in general. It is very important to individualize the ca...

How do you approach and manage anorexia and appetite loss in people with advanced cancer?

6
4 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Wisconsin

Anorexia/cachexia is often distressing to patients and families and it is this distress that is the target of many of the interventions for this syndrome as there are, in general, no effective therapies. Patients and families are routinely battling over the lack of eating as this causes further disc...

How do you approach cardiac surveillance in an asymptomatic adult who received anthracycline-based chemotherapy for a childhood cancer and presents to you without an active survivorship program?

2 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Phoenix Childrens Medical Group

At our children's hospital, we are not allowed to follow patients >23 years old if they were not diagnosed and treated at our institution. However, we do offer a 1 time courtesy consultation in the survivor clinic. We request roadmaps and create a treatment summary for the patient, perform a history...

Do you routinely screen and replace Vitamin D in patients with ITP?

1
1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Children's Hospital of Philadelphia

I do not generally screen for vitamin D deficiency in ITP patients, but do recommend that all patients undergo routine screening as recommended by the American Academy of Pediatrics (pediatric provider) and have vitamin D deficiency identified and managed as appropriate for age in general, regardles...

What diagnostic workup is recommended when immune thrombocytopenia is present in multiple family members?

1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Children's Hospital of Philadelphia

Genetic testing and confirmation that this is indeed immune thrombocytopenia and not a familial thrombocytopenia syndrome.

What is the recommended fungal workup in an immunocompromised patient after 5 days of persistent fever?

1
3 Answers

Mednet Member
Mednet Member
Infectious Disease · University of Texas Southwestern Medical School

For any patient with fevers, I focus significantly on any symptoms that a patient might have, like headache, diarrhea, and sinus symptoms, and work up a differential diagnosis based on possible pathogens in this area. If I am not finding anything, I would obtain a CT chest/abd/pelvis, as both invasi...

What is your preferred frontline regimen for metastatic unresectable fibrolamellar carcinoma in an AYA patient?

1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · FibroFighters Foundation

We have successfully used GEMOX-LEN along with multidisciplinary locoregional tumor debulking to convert more than 50% of unresectable stage IV FLC to definitive R0 resection and surgical remission, nearly 100% achieving 0.00 circulating tumor DNA (we use Signatera): Ginters et al., GI Cancer Trial...

What would be your next line of therapy for a pediatric patient with T-ALL in first relapse who has not received a transplant?

1
1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · The University of Texas MD Anderson Cancer Center

These patients can be challenging to bring into remission, and a multi-agent salvage regimen should be considered. If the patient has not previously received nelarabine, it should be incorporated; re-treatment may also be considered in select cases. During the first cycle, dasatinib may be added in ...

Where do you anticipate positioning Mim8 (denecimig) alongside existing options within your hemophilia A prophylaxis approach, assuming regulatory approval (FRONTIER2)?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Pittsburgh Medical Center

It is hard to say at this point, but I suspect it will be similar to emicizumab - i.e., it will be more frequently than the currently available rebalancing agents. What remains to be seen is if it will replace emicizumab by way of better perceived efficacy or only if someone is deemed to have "faile...